These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 31070007)
21. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. Ghanim H; Abuaysheh S; Hejna J; Green K; Batra M; Makdissi A; Chaudhuri A; Dandona P J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 32044999 [TBL] [Abstract][Full Text] [Related]
22. Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients. Sun Y; Yan D; Hao Z; Cui L; Li G Med Sci Monit; 2020 Apr; 26():e921891. PubMed ID: 32240122 [TBL] [Abstract][Full Text] [Related]
23. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982 [TBL] [Abstract][Full Text] [Related]
24. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S; Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013 [TBL] [Abstract][Full Text] [Related]
25. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Ott C; Jumar A; Striepe K; Friedrich S; Karg MV; Bramlage P; Schmieder RE Cardiovasc Diabetol; 2017 Feb; 16(1):26. PubMed ID: 28231831 [TBL] [Abstract][Full Text] [Related]
26. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520 [TBL] [Abstract][Full Text] [Related]
27. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298 [TBL] [Abstract][Full Text] [Related]
28. Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin. Yoshida A; Matsubayashi Y; Nojima T; Suganami H; Abe T; Ishizawa M; Fujihara K; Tanaka S; Kaku K; Sone H J Clin Endocrinol Metab; 2019 Sep; 104(9):3647-3660. PubMed ID: 30811541 [TBL] [Abstract][Full Text] [Related]
29. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study. Shigiyama F; Kumashiro N; Fuchigami A; Hirose T Cardiovasc Diabetol; 2018 Jun; 17(1):86. PubMed ID: 29895330 [TBL] [Abstract][Full Text] [Related]
30. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853 [TBL] [Abstract][Full Text] [Related]
31. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445 [TBL] [Abstract][Full Text] [Related]
32. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. Phrommintikul A; Wongcharoen W; Kumfu S; Jaiwongkam T; Gunaparn S; Chattipakorn S; Chattipakorn N Br J Clin Pharmacol; 2019 Jun; 85(6):1337-1347. PubMed ID: 30767253 [TBL] [Abstract][Full Text] [Related]
33. Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes. Wang Y; Xu L; Yuan L; Li D; Zhang Y; Zheng R; Liu C; Feng X; Li Q; Li Q; Ma J Diabet Med; 2016 Dec; 33(12):1732-1736. PubMed ID: 26927445 [TBL] [Abstract][Full Text] [Related]
34. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Solini A; Giannini L; Seghieri M; Vitolo E; Taddei S; Ghiadoni L; Bruno RM Cardiovasc Diabetol; 2017 Oct; 16(1):138. PubMed ID: 29061124 [TBL] [Abstract][Full Text] [Related]
35. Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohort. Jensen M; Eickhoff MK; Persson F; Rossing P; Thiel S; Hansen SWK; Palarasah Y; Svenningsen P; Jensen BL Immunobiology; 2024 May; 229(3):152797. PubMed ID: 38518448 [TBL] [Abstract][Full Text] [Related]
36. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. Petrykiv S; Sjöström CD; Greasley PJ; Xu J; Persson F; Heerspink HJL Clin J Am Soc Nephrol; 2017 May; 12(5):751-759. PubMed ID: 28302903 [TBL] [Abstract][Full Text] [Related]
37. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792 [TBL] [Abstract][Full Text] [Related]
38. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea. Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717 [TBL] [Abstract][Full Text] [Related]
40. The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study. Emamgholipour S; Moradi N; Beigy M; Shabani P; Fadaei R; Poustchi H; Doosti M Diabetol Metab Syndr; 2015; 7():108. PubMed ID: 26613006 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]